Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomerica (BMRA) EPS (Weighted Average and Diluted) (2016 - 2026)

Biomerica's EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$0.44 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 8.33% to -$0.44 in Q1 2026 year-over-year; TTM through Feb 2026 was -$1.58, a 57.75% increase, with the full-year FY2025 number at -$2.16, up 23.94% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.44 in Q1 2026 for Biomerica, up from -$0.45 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BMRA hit a ceiling of $0.0 in Q3 2025 and a floor of -$2.57 in Q2 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.37 across 5 years, with a median of -$0.12 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 2470.0% in 2024 and later skyrocketed 100.12% in 2025.
  • Tracing BMRA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.12 in 2022, then increased by 25.0% to -$0.09 in 2023, then soared by 33.33% to -$0.06 in 2024, then plummeted by 650.0% to -$0.45 in 2025, then grew by 2.22% to -$0.44 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BMRA at -$0.44 in Q1 2026, -$0.45 in Q4 2025, and $0.0 in Q3 2025.